Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean‐Yves Blay, Margaret von Mehren, John Zalcberg et al.|The Lancet Oncology|2020Cited by 406
Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma PatientsJennifer R. Brown, Farrukh T. Awan, Matthew S. Davids et al.|Blood|2013Cited by 10